Blood Products Advisory Committee
This article was originally published in The Gray Sheet
Meeting March 25-26 in Bethesda, Maryland. On March 25, the committee is scheduled to review a product license application for a peptide based assay for antibody to hepatitis C virus and discuss donor screening for HTLV-II. On March 26, the committee will review two draft memoranda: "Revised Recommendations for Testing for Antibody to Anti-HCV" and "Licensing Requirements for Irradiated Blood Products." The committee also is scheduled to discuss extending the indications for intravenous immune globulin. Contact person is Linda Smallwood at (301) 227- 6700.
You may also be interested in...
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.